All posts by imreal

ASENSEI Joins Forces with SoundHound AI to Deliver ASENSEI Voice For Health and Fitness Coaching


“ASENSEI Voice will include voice-driven training experiences including custom wake words, conversational intelligence and real-time coaching feedback with a branded voice.”

ASENSEI, the company offering the easiest way to add form tracking and personalized coaching to sport and fitness products, is joining forces with SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice artificial intelligence to deliver ASENSEI Voice for authentic voice AI-driven health and fitness coaching.

Drawing on SoundHound’s 17-year history of developing cutting-edge voice AI, ASENSEI Voice will allow fitness brands to leverage ASENSEI’s proprietary movement recognition and coaching intelligence Software Development Kit to offer authentic voice AI-driven training experiences to users.

As connected fitness brands evolve to become more personalized and intuitive, this integration of voice technology with ASENSEI movement understanding and coaching intelligence will allow these companies to transform their touch-only devices into personalized, conversational coaching interfaces.

SoundHound currently provides AI voice software to leading brands worldwide, including Netflix, Pandora, Snap, Vizio, Hyundai, Mercedes-Benz and Qualcomm. Built on Speech-to-Meaning® and Deep Meaning Understanding® technologies, the company’s advanced voice AI platform provides exceptional speed and accuracy. Speech-to-Meaning technology tracks speech in real-time and understands the context, even before the user has finished speaking. Deep Meaning Understanding enables voice assistants to address multiple questions and filter results simultaneously.

“In coaching, the language we use, inflections we select, all influence the way an athlete responds to coaching cues we deliver. ASENSEI powers brands with motion capture and movement understanding, which also includes the ability to coach an athlete in real-time. Now through our collaboration with SoundHound we can build on the authenticity and personalization of each person’s experience, and continue to influence the outcome of someone’s movement quality, learning and enjoyment. We are thrilled to partner with SoundHound and enable our partners in connected health and fitness and connected studios to deliver deeper conversational AI driven experiences on their platforms,” says Blake Whitcomb, VP of Partnerships at ASENSEI.

“At SoundHound we believe every brand should have a voice and every person should be able to interact naturally with the products around them—by simply talking. ASENSEI’s incredible technology understands movement and puts the mind of an elite coach into any fitness brand’s software solutions. Our category leading voice AI will now bring that coach to life for every user, offering them a personalized, conversational training experience,” says Davide Petramala, Director, Business Development at SoundHound.

ASENSEI Voice will include early implementations of voice driven training experiences such as:

  • Custom Wake Words: Embrace your fitness or health brands value when users ask for you by name
  • Branded Voice: Build a new voice assistant, or scale existing on-screen talent.
  • Conversational Intelligence: Converts speech to meaning at the speed of thought.
  • Text to Speech: Delivers real-time coaching insights with a branded voice.

About SoundHound

SoundHound (Nasdaq: SOUN), a leading innovator of conversational intelligence, offers an independent voice AI platform that enables businesses across industries to deliver best-in-class conversational experiences to their customers. Built on proprietary Speech-to-Meaning® and Deep Meaning Understanding® technologies, SoundHound’s advanced voice AI platform provides exceptional speed and accuracy and enables humans to interact with products and services like they interact with each other—by speaking naturally. SoundHound is trusted by companies around the globe, including Hyundai, Mercedes-Benz, Pandora, Qualcomm, Netflix, Snap, Square, LG, VIZIO, KIA, and Stellantis. http://www.soundhound.com

About ASENSEI

Companies of all sizes use ASENSEI software to motion-capture their customers and make sense of their movement, so that they can offer personalized health and fitness experiences that onboard, engage and retain customers.

We offer the most widely deployed solution for 3D Computer Vision and Connected Apparel, running on high-powered phones or low-powered consumer electronics, using single or multiple cameras to capture individuals at home or in a room full of participants.

ASENSEI. Artificial Intelligence meets Athletic Intelligence

Learn more at http://www.asensei.ai

Share article on social media or email:

Contagious Cancer in Shellfish Sparks Investigation by International Team of Scientists


Michael Metzger, PhD

Michael Metzger, PhD,
Pacific Northwest Research Institute

“We don’t normally think of cancer as an infectious disease, but several transmissible cancers have recently been found in the wild, causing significant mortality—and marine bivalves, such as mussels, oysters, cockles, scallops, and clams appear particularly susceptible,” says Michael Metzger, PhD.

Michael Metzger, PhD, Assistant Investigator at Pacific Northwest Research Institute, in Seattle, WA, and a team of global co-investigators will study how a virus-like cancer spreads among basket cockles on the Pacific Coast and soft-shell clams on the Atlantic Coast through a $3 million grant from the National Science Foundation’s Division of Ocean Sciences.

“We don’t normally think of cancer as an infectious disease,” said Dr. Metzger. “But several transmissible cancers have recently been found in the wild, causing significant mortality—and marine bivalves, such as mussels, oysters, cockles, scallops, and clams appear particularly susceptible.”

What is unique about this cancer compared to human cancers is that it is transmissible. The cancerous cells themselves spread from one animal to another, much like a virus. This strain of cancer is known to negatively affect the marine environment, commercial aquaculture industries, and Native American communities that rely on bivalves as traditional food sources.

The newly funded project brings together a diverse team of marine biologists, population geneticists, mathematical modelers, cancer biologists, and genomic/molecular biologists from the following organizations and institutions across the globe: Suquamish Tribe, Puget Sound Restoration Fund (PSRF), Western Washington University, Bigelow Laboratory for Ocean Sciences (Maine) and Gloucester Marine Genomics Institute (Massachusetts), and City, University of London.

Over the next five years, the interdisciplinary collaborative will collect samples, analyze genomes, develop mathematical models, and measure disease progression.

“It takes expertise in tribal resource management, marine conservation, and infectious disease ecology to solve this complex problem,” said Ryan Crim, a PSRF marine biologist who has been working with the Suquamish Tribe in Washington state to restore marine habitats for more than a decade.

They found infectious cancer prevalent in local basket cockles, a favorite subsistence species for Tribal members that has become scarce in recent years.

Elizabeth Unsell, a marine biologist with the Suquamish Tribe, explained that the Tribe is motivated to work to restore local populations and learn more about the threats they may be facing.

“Increasing our awareness and understanding of the presence and severity of transmissible cancer in this favored bivalve species will give us tools to better understand population dynamics and inform management decisions,” said Unsell.

On the eastern U.S. coast, soft-shell clams are consistently one of the most valuable fisheries for Massachusetts each year and the species has a strong cultural and historical relevance in the region. Transmissible cancer in soft-shell clams has caused major losses in Massachusetts in the past, severely impacting the commercial fishery.

“By gaining a better understanding of the infection dynamics and mechanisms of transmissible cancer in soft-shell clams, we will be more effective at preventing or managing the disease to better conserve this precious natural resource,” said Tim O’Donnell, a freshwater and marine fish researcher at Gloucester Marine Genomics Institute.

“Understanding exactly how these bivalves fight or bounce back from this cancer directly impacts the survival of those species and the people who rely on them,” Dr. Metzger said. “If successful, we will come away with a far better understanding of how these transmissible cancers spread and what we can do to stop them.”

“I’m grateful that the NSF values this kind of interdisciplinary research,” Dr. Metzger said. “Without their funding, we couldn’t launch a study like this connecting genomic analysis of the cancers with multi-year ecological surveys and modeling to understand all the factors involved in disease spread.”

###

ABOUT PNRI:

Pacific Northwest Research Institute (PNRI) is a nonprofit biomedical research institute, where scientists are using innovative approaches in genetics and genomics to tackle some of the most difficult problems in science and medicine. The institute was founded 67 years ago in Seattle, Washington, as a place where scientists were free to pursue discoveries that promised the highest chance of improving human health. The goal was at the beginning, and remains today, to conduct foundational science leading to impactful medical innovations. To learn more, visit pnri.org.

Share article on social media or email:

Practical Aspects of Clinical and Laboratory Diagnosis” Virtual Event, February 22nd, 2023


Don’t miss an opportunity to join Stago, an industry leader in the science of hemostasis and thrombosis, for a new educational webinar.

Stago to host their “Heparin-Induced Thrombocytopenia (HIT): Practical Aspects of Clinical and Laboratory Diagnosis” webinar on February 22nd, 2023, available any time after 1 pm Eastern Daylight time on the Labroots platform.

At Stago’s Virtual Event, expect to learn about Heparin-Induced Thrombocytopenia (HIT), a life-threatening complication following heparin exposure. The event will dive into the pathogenesis, incidence, clinical and laboratory diagnosis, as well as management of HIT.

Join this Virtual Event to:

  • Describe the role of antibody against PF4/heparin complexes in pathogenesis of HIT
  • Learn the clinical and laboratory criteria for screening and diagnosis of HIT
  • Describe the advantages and potential pitfalls of various laboratory tests for diagnosis of HIT
  • Understand the diagnosis and management algorithm for HIT in routine practice

To register for the event, and view the agenda, click here.

About Stago

Diagnostica Stago, Inc., (DSI) is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information, visit http://www.Stago-us.com.

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email:

Fairfax Virginia Based Physical Therapy Group Announces New Location


Physical Therapy in Fairfax VA

There is no one-size-fits-all approach to physical therapy for lower back pain as treatment plans are individualized to meet each patient’s specific needs. However, sour staff have performed many evidence based PT approaches to help our patients overcome chronic back pain.

Today, Virginian Physical Therapy & Staffing announced a new location in the Farifax Virginia. This new office, locate2810 Old Lee Hwy suite 200B, Fairfax, VA 22031, is the second of its kind in Northern VA and will house a growing number of healthcare professionals.

Dr. Aliyat Yimam, CEO, stated that the expansion was planned for a long time. Our vision was to reach the whole City and its surrounding areas. We are thrilled to serve the needs of the Fairfax City population, its surrounding residents, and our referring doctors and partners. We are also determined to expand our team and create healthcare jobs in Fairfax County.

Virginian Physical Therapy & Staffing of Fairfax is a rehabilitation center specializing in treating acute injuries from sports-related injuries, Running Therapy, Back, Knee, Neck, and Shoulder Pain Management Therapy, and automobile accidents. They are also experts in Post Surgery, Spinal Disease, and Neurological Therapy. Many of their staff are doctors of PT and PTS, with many years of experience, who are skilled at treating specialized health needs. The strategic move to add a new location will enable them to expand their patient care and reach tens of thousands of Virginia residents.

Dr. Yimam says, “there is no one-size-fits-all approach to physical therapy for lower back pain as treatment plans are individualized to meet each patient’s specific needs. However, some of the most commonly used physical therapy methods for lower back pain include:

Exercise and Stretching: Exercises that focus on strengthening the core muscles, improving flexibility, and reducing muscle imbalances can be beneficial for managing lower back pain.

Manual Therapy: Techniques such as massage, mobilization, and manipulation can help to alleviate pain and improve mobility in the lower back.

Electrical Stimulation: Applying electrical stimulation to the affected area can help reduce pain, improve muscle strength, and reduce muscle spasms.

Heat and Ice Therapy: Alternating between heat and ice therapy can help reduce pain and swelling in the affected area.”

Virginian Physical Therapy & Staffing of Fairfax

Virginian Physical Therapy & Staffing of Fairfax specializes in rehabilitating acute musculoskeletal injuries, such as those caused by auto accidents, sports, and work-related injuries. Our healthcare providers collaborate with primary care physicians, pain management doctors, physical therapists, and even orthopedists to provide and manage patient care. For more information, visit the website at https://vaphysicaltherapypro.com/fairfax-va/

About Client Surge SEO Team

The Client Surge SEO Team is a leader in providing small business advisory services, sales training, and business consulting. Our team supports companies in revenue generation, profit maximization, and business processes. We tailor our programs to meet your needs and generate long-lasting results for your company. For more information, visit the website at http://www.clientsurgeseo.com/

Share article on social media or email:

IgE Profiles May Help Predict Which Peanut-allergic Children May Benefit Most from Oral Immunotherapy


AAAAI Logo

Researchers observed that those who achieved SU despite stopping oral immunotherapy had different baseline peanut protein and epitope IgE profiles than those who achieved transient desensitization.

Research being presented during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) indicates that baseline epitope-specific IgE profiles may be predictive of achieving sustained unresponsiveness (SU) after completion of peanut oral immunotherapy.

The peanut Bead-Based Epitope Assay (BBEA) is a molecular diagnostic test that quantifies antibody binding to peanut epitopes, which are specific regions of the peanut proteins that are recognized by human antibodies. Peanut epitopes can help distinguish different types of peanut allergy, which is not possible with currently available testing methods, such as skin testing or whole-protein peanut IgE. A patient who is truly allergic to peanut has an IgE epitope binding profile that differs from a patient who may be sensitized but is not clinically reactive. In addition to having a sensitivity of 92% and a specificity of 94%, this test has a 93% concordance to results of a peanut oral food challenge, which is the gold standard for diagnosing food allergy.

Researchers examined patients from the POISED trial, who were randomized to peanut or a placebo for 24 months. Following this, desensitized patients either consumed no peanut or 300mg of peanut over the next 12 months. Researchers then determined SU by assessing which patients could pass a four-gram peanut oral food challenge.

Researchers measured IgE to peanut and peanut component proteins, IgG4 to peanut, and IgE and IgG4 to 64 allergenic peanut epitopes. Machine learning models were used to predict SU. Researchers observed that those who achieved SU despite stopping oral immunotherapy had different baseline peanut protein and epitope IgE profiles than those who achieved transient desensitization (i.e. those who passed their food challenges at the end of desensitization but did not pass the “final” food challenge at 156 weeks).

The machine learning model developed by researchers predicted SU with an 87% accuracy rate. Due to the limited sample size, resampling was used to predict SU rather than traditional training and testing sets.

Visit aaaai.org to learn more about OIT. Research presented at the AAAAI Annual Meeting, February 24-27 in San Antonio, Texas, is published in an online supplement to The Journal of Allergy and Clinical Immunology.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. The AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

Creating Healthier Communities’ National Board of Directors


Anne Mai Bertelsen Elected to CHC National Board of Directors

“I was drawn to CHC by its compelling equity mission,” said Bertelsen. “I look forward to sharing my insights and contributing as much as I can to help CHC as we work together to create healthier communities for all people.”

CHC: Creating Healthier Communities, a national nonprofit that removes the barriers to good health and equity, today announced that Anne Mai Bertelsen was unanimously elected to its national board of directors. Bertelsen will join her first board meeting March 1-2, 2023.

“It’s a privilege leading the CHC Board,” said Adam Rothschild, investor, consultant and CHC board chair. “We’re intentional about recruitment as this is a working board of active, engaged, top leaders, all deeply committed to equity and community health. I’m delighted to welcome Anne to this talented, diverse group and look forward to working with her.”

Bertelsen is a Fortune 500 global senior leader with 25+ years’ experience helping brands in highly regulated industries transform for growth. Most recently she led retail banking at Flagstar Bank as Executive Vice President where she worked to close financial health inequities and democratize access to financial advice, services and products. Prior to Flagstar, Bertelsen was a Managing Director at Accenture, the world’s largest global consulting firm, where she led a global team of financial service practitioners to reimagine banking services and products. She’s also held roles with American Express as well as founding and leading a boutique strategic consulting firm.

“I was drawn to CHC by its compelling equity mission,” said Bertelsen. “I look forward to sharing my insights and contributing as much as I can to help CHC as we work together to create healthier communities for all people.”

Bertelsen is a sought-out speaker and thought leader on the business impact of digitization, disruptive business models and evolving customer expectations in regulated industries. She has advised on digital innovations for SXSW, a leading innovation conference; The White House Office of Innovation and Technology; and the NJ Chapter of the Red Cross. She holds a bachelor’s from Rutgers University and a master’s from New York University.

“Anne is a welcome addition to the Board of Directors,” said Thomas G. Bognanno, president and CEO at CHC. “Her significant global business expertise will help ensure CHC’s bright future as we continue to grow and advance our mission.”

ABOUT CHC: CREATING HEALTHIER COMMUNITIES

CHC: Creating Healthier Communities brings nonprofits, businesses and communities together to improve community health. Our focus is health equity, addressing underlying issues and removing barriers so everyone can thrive. Our work is driven by community need, and we direct programs, resources and support where they have the greatest impact. Together with partners, we’ve been creating healthier communities for more than 65 years. Join us at chcimpact.org or @chcimpact.

Share article on social media or email:

New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition in Phase 2 Clinical Trial


Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no FDA-approved treatments specifically targeting this disorder.

But a new study, published in the New England Journal of Medicine, suggests that patients experiencing the moderate-to-severe itching associated with the disorder could potentially get relief with oral difelikefalin. The research was led by investigators at the Icahn School of Medicine at Mount Sinai.

Currently, difelikefalin—a selective kappa-opioid receptor agonist—is only FDA-approved as an injection for the treatment of moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis.

“For those who experience chronic itch of any kind, relief can sometimes seem unattainable,” said principal investigator Brian S. Kim, MD, MTR, FAAD, the Sol and Clara Kest Professor of Dermatology, Vice Chair of Research, and Director of the Mark Lebwohl Center for Neuroinflammation and Sensation at Icahn Mount Sinai. “In this Phase 2 trial, treatment with difelikefalin resulted in a reduction in the intensity of itch in patients with notalgia paresthetica.”

In the double-blind, placebo-controlled trial, patients with moderate-to-severe itching from notalgia paresthetica were randomly assigned in a 1:1 ratio to receive oral difelikefalin 2 mg or a placebo twice daily for eight weeks. The primary outcome was the change over eight weeks in the weekly mean of the daily Worst Itch Numeric Rating Scale, in which 0 is “no itch” and 10 is “worst itch imaginable.” Secondary clinical outcomes were itch-related quality-of-life and itch-related sleep measures.

Of 126 enrolled patients, 62 were assigned to receive difelikefalin and 63 to receive placebo. The baseline mean score on the Worst Itch Numeric Rating Scale was 7.6 (severe itch) in each group. The reduction from baseline in the worst itch score at week eight was 4.0 points in patients receiving difelikefalin versus 2.4 points for patients receiving placebo. Secondary outcomes were generally not supportive of the primary analysis. Headache, dizziness, constipation, and increased urine output occurred with difelikefalin.

Larger trials are needed to better assess the efficacy and safety of difelikefalin in notalgia paresthetica. If progress continues in a Phase 3 clinical trial, this medication would be the first FDA-approved drug specifically for people with notalgia paresthetica.

“The encouraging results achieved in this trial could reenergize the field and mark an important step toward improving symptoms of itch for patients with notalgia paresthetica,” said Dr. Kim, senior author of the paper, titled “Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.”

Additional co-authors are Mark Lebwohl, MD (Icahn Mount Sinai); Robert Bissonnette; (Innovaderm Research), and Kristine Nograles, Catherine Munera; Nilam Shah; Alia Jebara; Josh Cirulli; Joana Goncalves; all with Cara Therapeutics, Inc., the funder of the trial and manufacturer of difelikefalin.

Dr. Kim and Dr. Lebwohl are paid consultants/advisors to Cara Therapeutics.

The trial is registered on ClinicalTrials.gov (NCT04706975).

-####-

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

Share article on social media or email:

Slone Partners Places Gayarthri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics


Juvena

“Gayathri Swaminath and Eddie Moler are both highly accomplished and respected thinkers and leaders in drug discovery and development and data science with a truly impressive depth of knowledge,” said Slone Partners President Tara Kochis.

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Edward Moler, PhD as Vice President of Data Science and Gayathri Swaminath, PhD, MBA as Senior Vice President of Discovery at Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins.

Gayathri Swaminath, PhD, MBA brings more than 17 years of preclinical and translational research and drug development experience. Her leadership and extensive drug development experience at Amgen, Merck, and Greenfire Bio align with the company’s drug discovery interests across multiple therapeutic areas, including cardio-metabolic, pulmonary, inflammatory ophthalmology, renal, and fibrotic diseases.

Edward Moler, PhD brings more than 20 years of experience in bioinformatics, predictive modeling, biomarker and diagnostics discovery, machine learning, Omics, cell-based assay technology, and automation. He has held leadership and senior roles at Novartis, GE Healthcare, Quest Diagnostics, Tethys Bioscience, and the US Department of Energy.

“Gayathri Swaminath and Eddie Moler are both highly accomplished and respected thinkers and leaders in drug discovery and development and data science with a truly impressive depth of knowledge,” said Slone Partners President Tara Kochis. “They bring a tremendous amount of experience, dedication, passion, and talent to Juvena’s leadership team.”

“We are thrilled to announce the addition of Gayathri and Eddie to the team. Their expertise and experience will be invaluable as we continue our mission to unlock the therapeutic potential of secreted proteins and engineer them into life-saving therapeutics,” said Dr. Hanadie Yousef, CEO and co-founder of Juvena. “With this talented management team on board along with the outstanding experienced scientists and engineers who have joined our growing team, we will continue to scale our platform and pipeline to develop innovative treatments to rejuvenate lives for patients in need.”

Gayathri Swaminath completed her Ph.D. from the University of Hyderabad, India, and her postdoctoral fellowship at Stanford University, and holds an MBA from Cornell University. Edward Moler received a PhD in Chemistry from UC Berkeley and a BS in Chemistry from Texas A&M University.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT JUVENA THERAPEUTICS

Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. Secreted proteins are a class of biologics with proven therapeutic potential that has been under-leveraged due to the complexity of identifying and screening such proteins. The company is developing a patent-pending computational drug discovery and development platform that is delivering novel biologics to address major unmet medical needs in chronic and age-related diseases by mining regenerative proteins secreted by diverse types of human stem cells. Juvena has generated hits and new drug targets across several therapeutic areas. To learn more about Juvena Therapeutics, visit JuvenaTherapeutics.com or follow the company on LinkedIn @Juvena-Therapeutics.

Share article on social media or email:

Health Data Movers Strengthens Leadership Team and Promotes Karla Christopher, Brandon Camp and Michael Martin


Health Data Movers (HDM), a “Best in KLAS” healthcare technology services firm, is pleased to announce the promotions of Karla Christopher to Vice President of Delivery, Brandon Camp to Vice President of Delivery and Michael Martin to Senior Director of Delivery.

Karla Christopher

In her new role, Karla Christopher will oversee HDM’s Data Migration, Integration, and Custom Development service lines. A seasoned healthcare technology professional with more than 20 years of experience, Ms. Christopher first joined HDM in 2020 to lead engineering teams, with a focus on custom development and integration solutions. During her tenure, Ms. Christopher has grown HDM’s engineering capabilities and expertise, in addition to expanding the company’s customer base to include specialty labs and innovation centers. As healthcare providers, biotech firms, and digital health companies require greater technical expertise and sophistication, Ms. Christopher will innovate solutions to clients’ challenges through a winning team of app builders, system modernizers, and integrators.

Brandon Camp

Brandon Camp will lead HDM’s Applications, PMO, and Advisory service lines. A veteran Epic consultant and project manager/director, Mr. Camp began his HDM career in 2020 and quickly amassed an impressive record of successful long-term engagements in the PMO and Clinical Technologies disciplines. Core to HDM’s business since the company’s inception, the foundational service lines overseen by Mr. Camp will continue to exceed clients’ staffing and resourcing expectations, with his service line teams acting as a true partner to organizations in their implementations, optimizations, and support engagements.

Michael Martin

Working closely with Ms. Christopher, Michael Martin will manage the Data Migration, Integration, and Custom Development teams. Like Ms. Christopher and Mr. Camp, Mr. Martin also joined HDM in 2020 and immediately displayed his prowess in connecting systems and data through major successful conversions at large health system clients. Mr. Martin’s ability to collaborate with clients to drive execution of complex projects across provider, biotech, and digital health organizations will enable HDM’s data-driven clients to build true competitive advantage through technology.

“We are thrilled to promote Karla Christopher, Brandon Camp, and Michael Martin to these key leadership positions over our core services,” Greg Georgatos, HDM’s President and the executive leader of Delivery, said. “Their contributions to the company, coupled with their grit, integrity, and inclusivity with growth-oriented mindsets have been invaluable, and we are confident that they will continue to drive the company’s success and strategy execution in the years to come.”

About Health Data Movers (HDM)

Health Data Movers is dedicated to empowering patients and providers by unleashing the potential of healthcare data and technology. Our core services enable healthcare providers, biotechnology firms, and digital health companies to execute implementations, optimize and support systems while managing, moving, and sharing data in an efficient, secure, and compliant manner. Recognized as a leader in the industry, HDM received the Best in KLAS award in 2022 and has been named to the Inc. 5000 list three times (2020, 2021, 2022). Additionally, HDM was honored as one of the “Best Firms to Work For” by Consulting Magazine in 2020.

For more information about Health Data Movers and its services, please visit:

https://www.healthdatamovers.com

Share article on social media or email:

Elder Law Attorney Diane Weinberg Named to Super Lawyers List for 2023


News Image

Protecting the rights of seniors and individuals with disabilities is my passion and I am proud to be recognized for my work in this important area of law.

Weinberg Elder Law, LLC announced today that Founder Diane Weinberg has been named to the Super Lawyers of Georgia 2023 list. This is Weinberg’s fourth consecutive year to receive this recognition. Only the top five percent of the lawyers in each the state qualify for the Super Lawyers list.

“It is a true honor to be named to the Super Lawyers list for the fourth consecutive year,” said Weinberg. “Protecting the rights of seniors and individuals with disabilities is my passion and I am proud to be recognized for my work in this important area of law.”

Super Lawyers, a Thomson Reuters business, is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high degree of peer recognition and professional achievement. Super Lawyers uses a patented multiphase selection process that includes peer nominations and evaluations combined with independent research. Each candidate is evaluated on 12 indicators of peer recognition and professional achievement. Selections are made on an annual, state-by-state basis, and no more than five percent of the lawyers in the state are selected to receive this honor.

Super Lawyers does not permit attorneys to pay to be on the list, and no purchase of any product is required for inclusion on Super Lawyers. The process is completely objective and results in a list that the public can use with confidence to find truly exceptional lawyers in their area. For more information about Super Lawyers, visit SuperLawyers.com.

ABOUT WEINBERG ELDER LAW

Weinberg Elder Law, LLC provides legal services designed to help Georgia’s seniors and their families navigate the complex process of aging. Founder Diane Weinberg, JD, is a member of the State Bar of Georgia, a member of the Atlanta Bar Association, Academy of Special Needs Planners, and the National Academy of Elder Law Attorneys. She is also the State Ambassador for the Georgia Chapter of the National Academy of Elder Law Attorneys. Ms. Weinberg is the only private practice attorney in Georgia to have earned certification as an ACT (At Risk Adult Certification Training) offered through the Georgia Department of Human Services, Division of Aging Services. For more information, visit http://www.weinbergelderlaw.com

Share article on social media or email: